SG11201507408XA - Substituted aromatic compounds and related method for the treatment of fibrosis - Google Patents

Substituted aromatic compounds and related method for the treatment of fibrosis

Info

Publication number
SG11201507408XA
SG11201507408XA SG11201507408XA SG11201507408XA SG11201507408XA SG 11201507408X A SG11201507408X A SG 11201507408XA SG 11201507408X A SG11201507408X A SG 11201507408XA SG 11201507408X A SG11201507408X A SG 11201507408XA SG 11201507408X A SG11201507408X A SG 11201507408XA
Authority
SG
Singapore
Prior art keywords
fibrosis
treatment
aromatic compounds
substituted aromatic
related method
Prior art date
Application number
SG11201507408XA
Inventor
Boulos Zacharie
Shaun Abbott
Lyne Gagnon
Pierre Laurin
Brigitte Grouix
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of SG11201507408XA publication Critical patent/SG11201507408XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • A61P33/12Schistosomicides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
    • C07C53/134Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
SG11201507408XA 2013-03-15 2014-03-14 Substituted aromatic compounds and related method for the treatment of fibrosis SG11201507408XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361798269P 2013-03-15 2013-03-15
PCT/CA2014/000236 WO2014138906A1 (en) 2013-03-15 2014-03-14 Substituted aromatic compounds and related method for the treatment of fibrosis

Publications (1)

Publication Number Publication Date
SG11201507408XA true SG11201507408XA (en) 2015-10-29

Family

ID=51535669

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201507408XA SG11201507408XA (en) 2013-03-15 2014-03-14 Substituted aromatic compounds and related method for the treatment of fibrosis

Country Status (26)

Country Link
US (3) US10023518B2 (en)
EP (1) EP2970089B1 (en)
JP (1) JP6448562B2 (en)
KR (1) KR102196721B1 (en)
CN (2) CN110105200B (en)
AR (1) AR095429A1 (en)
AU (1) AU2014231648B2 (en)
BR (1) BR112015022008A2 (en)
CA (1) CA2905621C (en)
CL (1) CL2015002535A1 (en)
DK (1) DK2970089T3 (en)
EA (1) EA030651B1 (en)
ES (1) ES2741439T3 (en)
HK (1) HK1220440A1 (en)
IL (1) IL241178B (en)
MX (1) MX2015011878A (en)
MY (1) MY180305A (en)
NZ (1) NZ712797A (en)
PH (1) PH12015502011B1 (en)
PL (1) PL2970089T3 (en)
PT (1) PT2970089T (en)
SG (1) SG11201507408XA (en)
TW (1) TWI689490B (en)
UY (1) UY35402A (en)
WO (1) WO2014138906A1 (en)
ZA (1) ZA201507061B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6437452B2 (en) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
KR102403306B1 (en) 2013-01-15 2022-06-02 인사이트 홀딩스 코포레이션 Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
TWI742541B (en) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis
JP2016528298A (en) 2013-08-23 2016-09-15 インサイト・コーポレイションIncyte Corporation Furopyridine and thienopyridinecarboxamide compounds useful as PIM kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
CN106999458B (en) * 2014-10-10 2021-04-13 普罗米蒂克医药Smt有限公司 Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
MX2017004733A (en) 2014-10-10 2017-07-17 Prometic Pharma Smt Ltd Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis.
KR20170072352A (en) * 2014-11-12 2017-06-26 프로메틱 파마 에스엠티 리미티드 Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration
KR102554476B1 (en) * 2015-03-18 2023-07-10 벡투스 바이오시스템즈 리미티드 Compositions for the Treatment of Kidney and/or Liver Diseases
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (en) 2015-09-09 2021-08-01 美商英塞特公司 Salts of a pim kinase inhibitor
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
JP7034914B2 (en) 2015-11-23 2022-03-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Anti-α-v integrin antibody for the treatment of fibrosis and / or fibrotic disease
US10463645B2 (en) * 2016-05-19 2019-11-05 Everfront Biotech Inc. Method for delaying the onset of pulmonary fibrosis or treating pulmonary fibrosis
US11547746B2 (en) 2016-12-15 2023-01-10 Talengen International Limited Method for treating coronary atherosclerosis and complications thereof
AR113922A1 (en) 2017-12-08 2020-07-01 Incyte Corp LOW DOSE COMBINATION THERAPY FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
KR102126389B1 (en) * 2018-09-14 2020-06-25 셀라이온바이오메드 주식회사 A composition for preventing or treating liver diseases comprising benzhydrylthio acetamide derivative as an active ingredient
MX2023004137A (en) * 2020-10-06 2023-06-22 Pharmaceutique Ingenew Inc Substituted aromatic compounds and pharmaceutical compositions thereof.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183519A1 (en) * 2001-03-13 2002-12-05 Herbert Nar Antithrombotic carboxylic acid amides
WO2007140189A2 (en) * 2006-05-26 2007-12-06 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted carboxylic acid compounds
JP5544169B2 (en) * 2007-02-08 2014-07-09 エミスフェアー・テクノロジーズ・インク Phenylalkylcarboxylic acid derivative delivery agent
AU2010244938A1 (en) * 2009-05-04 2011-11-17 Prometic Pharma Smt Limited Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof
PL2427416T3 (en) * 2009-05-04 2016-09-30 Substituted aromatic compounds and pharmaceutical uses thereof
AT509045B1 (en) * 2010-01-29 2011-06-15 Planta Naturstoffe Vertriebsges M B H COMPOUNDS FOR THE TREATMENT OF ASTHMA BRONCHIALE

Also Published As

Publication number Publication date
AU2014231648A1 (en) 2015-10-22
WO2014138906A1 (en) 2014-09-18
MY180305A (en) 2020-11-27
PT2970089T (en) 2019-09-04
CA2905621A1 (en) 2014-09-18
US10550066B2 (en) 2020-02-04
US20160039736A1 (en) 2016-02-11
JP6448562B2 (en) 2019-01-09
CL2015002535A1 (en) 2016-03-28
BR112015022008A2 (en) 2021-05-25
ES2741439T3 (en) 2020-02-11
TW201441186A (en) 2014-11-01
UY35402A (en) 2014-10-31
NZ712797A (en) 2020-08-28
MX2015011878A (en) 2016-06-07
CN110105200B (en) 2022-04-12
PH12015502011A1 (en) 2016-01-11
AU2014231648B2 (en) 2018-02-08
EP2970089A1 (en) 2016-01-20
EP2970089A4 (en) 2016-10-12
US20200172462A1 (en) 2020-06-04
US11524930B2 (en) 2022-12-13
TWI689490B (en) 2020-04-01
IL241178B (en) 2020-09-30
DK2970089T3 (en) 2019-08-05
US20180237374A1 (en) 2018-08-23
US10023518B2 (en) 2018-07-17
PH12015502011B1 (en) 2016-01-11
IL241178A0 (en) 2015-11-30
EP2970089B1 (en) 2019-05-08
EA201591775A1 (en) 2016-05-31
CN110105200A (en) 2019-08-09
PL2970089T3 (en) 2020-01-31
KR20160051676A (en) 2016-05-11
KR102196721B1 (en) 2020-12-30
CN105189438A (en) 2015-12-23
AR095429A1 (en) 2015-10-14
HK1220440A1 (en) 2017-05-05
JP2016512202A (en) 2016-04-25
ZA201507061B (en) 2017-03-26
CA2905621C (en) 2021-06-29
EA030651B1 (en) 2018-09-28

Similar Documents

Publication Publication Date Title
HK1220440A1 (en) Substituted aromatic compounds and related method for the treatment of fibrosis
HK1220610A1 (en) Pyridazinone compounds and methods for the treatment of cystic fibrosis
HK1232147A1 (en) Cenicriviroc for the treatment of fibrosis
EP2968285A4 (en) Compounds and methods for the treatment of cystic fibrosis
EP2970317A4 (en) Pyrimido-diazepinone compounds and methods of treating disorders
EP2991953A4 (en) Composition for treatment of stone and method for making the same
HK1224210A1 (en) Methods and compositions for treatment of fibrosis
EP2968321A4 (en) Compounds for treatment of fibrosis diseases
EP3068387A4 (en) Compounds and methods for the treatment of malaria
EP3016944A4 (en) Compounds for treatment of cystic fibrosis
HK1220374A1 (en) Compositions and methods for the treatment of carboxyhemoglobinemia
GB201200688D0 (en) Aromatic compounds and methods of making the same
HK1247558A1 (en) Cenicriviroc for the treatment of fibrosis
HK1244692A1 (en) Methods of treating fibrosis
ZA201507475B (en) Method for the treatment of gas
GB201303589D0 (en) Compound and method for the treatment of neurodegenerative conditions
EP3074038A4 (en) Method of treating nephropathy
IL241096A0 (en) Method of treatment
HK1221681A1 (en) Methods for the treatment of neurodegeneration
HK1204991A1 (en) Perm treatment method
GB201311984D0 (en) Methods and compounds for preventing or treating osteoarthritis
GB201301975D0 (en) New method for the purpose of safening
GB201322778D0 (en) Method of treatment
GB201314882D0 (en) Method of treatment
AU2013904595A0 (en) Method of treating nephropathy